CA21113 “Genome Editing to Treat Humans Diseases” (GenE-Humdi)

Datos básicos

Código del Financiador:

EU23/04

Año Inicial:

2023

Año final:

2026

Objetivos del proyecto

The principal aim of the GenE-HumDi Action is to bring together pharmaceutical companies, academic institution, science and regulatory agencies, biotechnology firms, patient advocacy association and information technology, in order to tackle knowledge fragmentation with the aim to accelerate the translation of GE technologies to the treatment of human diseases.